-
1
-
-
0037099732
-
Evaluation of HER-2/neu gene amplification and overexpression
-
Press MF, Slamon DJ, Flora KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression. J Clin Oncol, 2002, 20: 3095-3105.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3095-3105
-
-
Press, M.F.1
Slamon, D.J.2
Flora, K.J.3
-
2
-
-
1542647611
-
Targeted therapy for cancer: the HER-2/neu and herceptin story
-
Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and herceptin story. Clin Leadersh Manag, Rev, 2003, 17: 333-340.
-
(2003)
Clin Leadersh Manag, Rev
, vol.17
, pp. 333-340
-
-
Ross, J.S.1
Gray, G.S.2
-
3
-
-
0035257578
-
New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin)
-
Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol, 2001, 28 Suppl 3: 1-12.
-
(2001)
Semin Oncol
, vol.28
, Issue.SUPPL. 3
, pp. 1-12
-
-
Nabholtz, J.M.1
Slamon, D.2
-
4
-
-
0037023986
-
Real-world performance of HER2 testing: national surgical adjuvant breast and bowel project experience
-
Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing: national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst, 2002, 94: 852-854.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 852-854
-
-
Paik, S.1
Bryant, J.2
Tan-Chiu, E.3
-
5
-
-
0037024478
-
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
-
Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst, 2002, 94: 855-857.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 855-857
-
-
Roche, P.C.1
Suman, V.J.2
Jenkins, R.B.3
-
6
-
-
17844376512
-
Comparison of Immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice
-
Dolan M, Snover D. Comparison of Immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol, 2005, 123: 766-770.
-
(2005)
Am J Clin Pathol
, vol.123
, pp. 766-770
-
-
Dolan, M.1
Snover, D.2
-
7
-
-
33745153139
-
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2 + in immunohistochemical analysis
-
Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2 + in immunohistochemical analysis. Eur J Cancer, 2006, 42: 1501-1506.
-
(2006)
Eur J Cancer
, vol.42
, pp. 1501-1506
-
-
Merola, R.1
Mottolese, M.2
Orlandi, G.3
-
8
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer
-
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med, 2005, 353: 1673-1684.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
9
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344: 783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
10
-
-
33845914783
-
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
-
Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 2007, 369: 29-36.
-
(2007)
Lancet
, vol.369
, pp. 29-36
-
-
Smith, I.1
Procter, M.2
Gelber, R.D.3
-
11
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 2002, 20: 719-726.
-
(2002)
J Clin Oncol
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
12
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005, 353: 1659-1672.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
13
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med, 2006 354: 809-820.
-
(2006)
N Engl J Med
, vol.354
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.L.2
Bono, P.3
-
14
-
-
0042566053
-
Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification
-
Lal P, Salazar PA, Ladanyi M, et al. Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification J Mol Diagn, 2003, 5: 155-159.
-
(2003)
J Mol Diagn
, vol.5
, pp. 155-159
-
-
Lal, P.1
Salazar, P.A.2
Ladanyi, M.3
-
15
-
-
3042622482
-
HER-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues
-
Owens MA, Horten BC, Da Silva MM. HER-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 2004, 5: 63-69.
-
(2004)
Clin Breast Cancer
, vol.5
, pp. 63-69
-
-
Owens, M.A.1
Horten, B.C.2
Da Silva, M.M.3
-
16
-
-
73649147338
-
HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry
-
Kovács A, Stenman G. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry. Pathol Res Pract, 2010, 206: 39-42.
-
(2010)
Pathol Res Pract
, vol.206
, pp. 39-42
-
-
Kovács, A.1
Stenman, G.2
-
17
-
-
17144414443
-
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer
-
Lottner C, Schwarz S, Diermeier S, et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol, 2005, 205: 577-584.
-
(2005)
J Pathol
, vol.205
, pp. 577-584
-
-
Lottner, C.1
Schwarz, S.2
Diermeier, S.3
-
18
-
-
28544452873
-
Histopathologic characteristics predicting HER-2/neu amplification in breast cancer
-
Prati R, Apple SK, He J, et al. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J, 2005, 11: 433-439.
-
(2005)
Breast J
, vol.11
, pp. 433-439
-
-
Prati, R.1
Apple, S.K.2
He, J.3
-
19
-
-
2142758687
-
HER-2 testing in breast cancer using parallel tissue-based methods
-
Yaziji H, Goldstein L, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 2004, 291: 1972-1977.
-
(2004)
JAMA
, vol.291
, pp. 1972-1977
-
-
Yaziji, H.1
Goldstein, L.2
Barry, T.S.3
-
20
-
-
77957101699
-
Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India
-
Panjwani P, Epari S, Karpate A, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India. Indian J Med Res, 2010, 132: 287-294.
-
(2010)
Indian J Med Res
, vol.132
, pp. 287-294
-
-
Panjwani, P.1
Epari, S.2
Karpate, A.3
-
21
-
-
0346500480
-
Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay
-
Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol, 2004, 121: 70-77.
-
(2004)
Am J Clin Pathol
, vol.121
, pp. 70-77
-
-
Varshney, D.1
Zhou, Y.Y.2
Geller, S.A.3
-
22
-
-
54449091620
-
Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing
-
Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol, 2008, 26: 4869-4874.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4869-4874
-
-
Vanden Bempt, I.1
Van Loo, P.2
Drijkoningen, M.3
-
23
-
-
0037440261
-
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
-
Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst, 2003, 95: 142-153.
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 142-153
-
-
Konecny, G.1
Pauletti, G.2
Pegram, M.3
-
24
-
-
0038575385
-
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer
-
Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol, 2003, 200: 290-297.
-
(2003)
J Pathol
, vol.200
, pp. 290-297
-
-
Witton, C.J.1
Reeves, J.R.2
Going, J.J.3
-
25
-
-
33847159947
-
HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive
-
Olsen DA, Østergaard B, Bokmand S, et al. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med, 2007, 45: 177-182.
-
(2007)
Clin Chem Lab Med
, vol.45
, pp. 177-182
-
-
Olsen, D.A.1
østergaard, B.2
Bokmand, S.3
|